about
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?SnapShot: Multiple Myeloma[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Cereblon binding molecules in multiple myeloma.Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia.Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.[Multiple myeloma].Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.[(11) C]Methionine emerges as a new biomarker for tracking active myeloma lesions.CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.Loss of FAM46C Promotes Cell Survival in Myeloma.The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma.Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesThe Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple MyelomaResults of the first bortezomib-based induction therapy in the treatment of multiple myelomaIntegrin-linked kinase is dispensable for multiple myeloma cell survivalProtocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple MyelomaCIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System InvolvementSpectrum and functional validation of PSMB5 mutations in multiple myelomaAssessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line modelResponse to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donorDifferent MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsCarfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers
P50
Q30833823-19090E72-D2CC-4A73-B9F6-3EB6405C3BE0Q36306807-3CF029F5-C6C4-4531-9E3D-2BACB0DED89AQ36548064-775091A8-CD55-4384-83F0-5663FB935550Q36894316-638E11D0-E3A8-464E-BD76-1AAE1BA4C05CQ37541868-1E9E83A4-720A-49C2-B546-588A03A12800Q37822742-B6EAB06F-2713-4E2E-804E-04EEF7DB18EEQ38406398-2EF667B6-E780-4851-91CD-7104572D6146Q39560208-5C52A0D8-7493-43CC-B2AC-27E1FF86AEB3Q39982294-248481E7-79F4-478A-B2B8-8D4FE52277D6Q41455546-867FF30D-CE93-4DC8-B0F5-2A0245CC24D0Q41485437-FB9A7710-E354-44F7-8F6C-8ABCD12CD149Q41766580-DD26C95F-1C4D-40E3-B26F-99CCACCC94EFQ42399854-B85922E3-AD79-45AA-9E3D-3D1BC326099CQ44900380-D8AF7549-2001-4AFD-B0E2-CD7EFA384995Q48177136-E3442E1F-AC6D-4859-81F5-7839C2494AB1Q48201554-669997BC-A79A-4E4B-9EF4-D20EDC55EC86Q49660927-1548666C-075E-4842-B3B8-4CBBBA5700B6Q50942246-16B15ED2-D5E1-434B-9510-83E9DDFF8C8FQ52950828-0147760C-2D64-4654-8409-7B0F043665FDQ60488094-320D622C-FC8F-4158-9D0E-CE0FBA692980Q64103324-85CF633D-A01B-4437-BB92-5F522BE84324Q84067921-583900B7-5F62-4A71-9450-4DB323C146E2Q84278586-935AE75A-8A67-471A-B430-290449B877F9Q88802746-13D2215C-13CF-4DA1-AEB4-997DD589F0A5Q89647087-1BD4AFAD-76FF-4173-806F-2B76FEA4B721Q90351167-FD5E9A88-6C93-4B2F-999D-A92504874EEEQ91619930-843DB7ED-BC1F-44F2-97E2-B954673EB42DQ91981420-016A82BA-08BE-42A4-9BA6-3B07934F1DCFQ92047383-3D7E8157-5807-461D-826C-F0C2648D9A59Q93262891-1BD74035-48B7-433C-A427-8B16655947E6Q93263287-B7C22034-A860-45DB-97E6-C88CF5332B95
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
M Kortüm
@en
M Kortüm
@nl
type
label
M Kortüm
@en
M Kortüm
@nl
prefLabel
M Kortüm
@en
M Kortüm
@nl
P31
P496
0000-0002-7011-0286